Our study provides population-level evidence confirming the causal relationship between reduced SFTPB protein levels and NSCLC risk, suggesting that SFTPB agonists could be a promising avenue for therapeutic prevention in high-risk individuals with lung cancer. The gene discussed is SFTPB; the disease is lung carcinoma.